New Stock Offering | Sunho Biologics (02898) is Now Available for Subscription with Minimum Fee of HK$2,727.22
M+ Global Updates 16/05/2024 10:41

Sunho Biologics Files Prospectus for IPO

Sunho Biologics $SUNHO BIO-B 02898.HK$ filed a prospectus for its upcoming initial public offering on the Hong Kong bourse, with about 34.2 million shares available for HK$13.5 apiece, plus charges, according to a filing with the bourse.

The application period will be available from May 16 and continue until May 21.

The shares include 30.7 million international shares and 3.4 million Hong Kong shares. The nominal value of each share is $0.0005.

The issue price is HK$13.50 per share and the minimum subscription amount, or entry fee, is around HK$2,727.22 for a board lot of 200 shares.

The pharmaceutical company's stock is expected to begin trading on May 24 under the ticker 2898.

(Please note: Cash subscription deadline is 20/05(HKT)10:00)

Prospectus of Sunho Biologics:

Company Profile

$SUNHO BIO-B 02898.HK$, established in 2018 in Huzhou, Zhejiang, is pioneering in the field of immunotherapy with a focus on treatments for cancer and autoimmune diseases. The company, noted by Frost & Sullivan as a leader in antibody-cytokine products, has developed nine products, with six in clinical and three in preclinical stages. Its integrated research and development capabilities encompass discovery through Good Manufacturing Practice (GMP) production. Shenghe has received regulatory approvals from China and the US for clinical trials of three of its innovative products, marking them among the fastest-progressing in their category worldwide.

How to Subscribe?

M+ Global has officially launched its new stock subscription feature for Hong Kong stocks. Investors can now easily subscribe to new stock offerings through our platform.

Wish you good luck and many profitable investments!

Finally, welcome to subscribe to our HK IPO BUZZ topic at to get the latest updates on Hong Kong IPOs 📈🔔✨.


The content is provided as general information only and should not be taken as investment advice. All the contents shall not be taken as a recommendation to buy or sell any security or financial instruments. Any action you take resulting from information, analysis, or commentary on this article is your responsibility. Please consult your investment advisor before making any investments.

Stay informed with updates through our Telegram and WhatsApp channels

Access the latest financial market news
Get expert insights

Scan QR to join